Screener
TG Therapeutics TGTX Proceeds from (Repayments of) Secured Debt
Proceeds from (Repayments of) Secured Debt at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromRepaymentsOfSecuredDebt.
The source filing: TG Therapeutics’s 10-Q, filed May 6, 2026. Open the filing →
- Filed
- May 6, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-015246
FAQ
- What is TG Therapeutics's proceeds from (repayments of) secured debt?
- TG Therapeutics (TGTX) reported proceeds from (repayments of) secured debt of -$255M in Q1 2026.
- What does proceeds from (repayments of) secured debt mean?
- Represents cash flows resulting from the issuance or repayment of debt backed by specific collateral. This reflects the company's use of secured financing to manage its capital structure.
Ask your AI about TG Therapeutics's proceeds from (repayments of) secured debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude